Cumberland Pharmaceuticals annual debt-to-ebitda ratio
2010
2011
2012
2014
2015
2016
2025
Cumberland Pharmaceuticals Debt-to-EBITDA Ratio Growth & History (CPIX)
Cumberland Pharmaceuticals's debt-to-ebitda ratio was 3.65 for fiscal 2025.
View full Cumberland Pharmaceuticals company overviewCumberland Pharmaceuticals annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.65 | — | — |
| 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| 2015 | 2015-12-31 | 0.00 | 0.00 | — |
| 2014 | 2014-12-31 | 0.00 | — | — |
| 2012 | 2012-12-31 | 0.00 | 0.00 | — |
| 2011 | 2011-12-31 | 0.00 | −0.36 | — |
| 2010 | 2010-12-31 | 0.36 | — | — |
Cumberland Pharmaceuticals quarterly debt-to-ebitda ratio
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.21
Q2.23
Q1.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 11.09 | — | — |
| Q3 2025 | 2025-09-30 | 96.28 | — | — |
| Q1 2025 | 2025-03-31 | 3.44 | — | — |
| Q2 2023 | 2023-06-30 | 13.26 | — | — |
| Q2 2021 | 2021-06-30 | 10.21 | — | — |
| Q1 2017 | 2017-03-31 | 0.00 | 0.00 | — |
| Q4 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| Q3 2016 | 2016-09-30 | 0.00 | 0.00 | — |
| Q2 2016 | 2016-06-30 | 0.00 | 0.00 | — |
| Q1 2016 | 2016-03-31 | 0.00 | 0.00 | — |
| Q4 2015 | 2015-12-31 | 0.00 | 0.00 | — |
| Q3 2015 | 2015-09-30 | 0.00 | 0.00 | — |
| Q2 2015 | 2015-06-30 | 0.00 | — | — |
| Q1 2015 | 2015-03-31 | 0.00 | — | — |
| Q4 2014 | 2014-12-31 | 0.00 | — | — |
| Q3 2014 | 2014-09-30 | 0.00 | 0.00 | — |
| Q3 2013 | 2013-09-30 | 0.00 | 0.00 | — |
| Q2 2013 | 2013-06-30 | 0.00 | 0.00 | — |
| Q1 2013 | 2013-03-31 | 0.00 | 0.00 | — |
| Q4 2012 | 2012-12-31 | 0.00 | 0.00 | — |
| Q3 2012 | 2012-09-30 | 0.00 | — | — |
| Q2 2012 | 2012-06-30 | 0.00 | — | — |
| Q1 2012 | 2012-03-31 | 0.00 | — | — |
| Q4 2011 | 2011-12-31 | 0.00 | — | — |
Cumberland Pharmaceuticals debt-to-ebitda ratio trends
Between the periods ended 2010-12-31 and 2025-12-31, Cumberland Pharmaceuticals's debt-to-ebitda ratio increased from 0.36 to 3.65, a change of 3.29. The latest reported quarter, Q4 2025, shows 11.09.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cumberland Pharmaceuticals source filings ↗